Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Oncomatryx
Deal Size : Undisclosed
Deal Type : Collaboration
TFS Expands Partnership with Oncomatryx for OMTX705 Pancreatic Cancer Trial
Details : The collaboration aims to advance the clinical development of OMTX705 in patients with advanced or metastatic pancreatic adenocarcinoma.
Product Name : OMTX705
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Oncomatryx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ANOC-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anocca gets Nod To Begin Human Trials in Advanced Pancreatic Cancer
Details : ANOC-001 is a novel discovery from Anocca’s platform that targets mutant KRAS G12V and will be evaluated in patients with mutated KRAS-positive advanced pancreatic cancer.
Product Name : ANOC-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : ANOC-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANOC-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anocca Submits VIDAR-1 Pancreatic Cancer Trial Application
Details : ANOC-001 is a T-cell receptor (TCR-T) cell therapy which targets mutant KRAS G12V, is being investigated in patients with advanced pancreatic cancer.
Product Name : ANOC-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : ANOC-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nadunolimab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia Reports Progress Towards DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia
Details : Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated in the IND-enabling studies for the treatment of acute myeloid leukemia.
Product Name : CAN04
Product Type : Antibody
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Nadunolimab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNG348
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Tango Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers.
Product Name : TNG348
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : TNG348
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Tango Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 177-Lu SN201
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 177Lu-SN201 has been optimally designed for physiological targeting by means of the EPR effect. Preclinical results from different tumor models confirm accumulations in tumors, inhibited tumor growth and extended survival.
Product Name : Tumorad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : 177-Lu SN201
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vididencel,Azacitidine
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Australasian Leukaemia & Lymphoma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to support Mendus to focus on the development of its lead product candidate DCP-001 (vididencel) in combination with oral azacitidine as a potential novel maintenance treatment in acute myeloid leukemia.
Product Name : DCP-001
Product Type : Vaccine
Upfront Cash : Undisclosed
June 12, 2023
Lead Product(s) : Vididencel,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Australasian Leukaemia & Lymphoma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 177-Lu SN201
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Spago Nanomedical has Submitted Application to Start Tumorad(R) Clinical Phase I/IIa Study
Details : 177Lu-SN201 is clinically effective against cancer. Combined with Spago Nanomedical´s carefully designed polymeric nanomaterial, the candidate promising new radionuclide therapy for physiological targeting and tumor selective treatment of cancer.
Product Name : Tumorad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : 177-Lu SN201
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HLX22,Serplulimab,Trastuzumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alligator out-licensed AC101 (HLX22) to the South Korean company AbClon, Inc. in 2016, who sub-licensed the drug candidate to Henlius Biotech for clinical and commercial development in China.
Product Name : AC101
Product Type : Antibody
Upfront Cash : Inapplicable
August 11, 2022
Lead Product(s) : HLX22,Serplulimab,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPD5
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dose escalation study on safety and tolerability of OPD5 as a myeloablative regimen followed by Autologous Stem Cell Transplantation in patients with relapsed refract...
Product Name : OPD5
Product Type : Peptide
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : OPD5
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable